PodcastPearls: Expert Insights on Optimal Use of CDK4/6 Inhibitors for HR-Positive/HER2-Negative Breast Cancer

Results from LUMINA trial showing very low local recurrence rate with omission of radiotherapy after breast-conserving surgery in patients with low-risk luminal A breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Exploratory analysis of EFS by residual cancer burden from KEYNOTE-522 evaluating neoadj pembrolizumab plus chemotherapy followed by adj pembrolizumab for early-stage TNBC, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

PALOMA-2 study: final OS analysis with palbociclib plus letrozole in ER-positive/HER2-negative advanced breast cancer, presented at ASCO 2022 and reported by Clinical Care Options (CCO)

Gain expert insight on managing NTRK- and RET-altered malignancies and optimal methods for detecting gene fusions, in this webcast from Clinical Care Options (CCO)

Alexander Drilon, MD
Program Director Thomas Stinchcombe, MD
Program Director Saad A. Khan, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: June 10, 2022 Expired: June 9, 2023